Literature DB >> 11872196

Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles.

David B Seifer1, David T MacLaughlin, Benjamin P Christian, Bo Feng, Robert M Shelden.   

Abstract

OBJECTIVE: To test the hypothesis that the concentration of early follicular phase serum müllerian-inhibiting substance (MIS) is associated with ovarian response in women undergoing ovulation induction in preparation for assisted reproductive technology (ART).
DESIGN: Retrospective analysis of frozen day 3 serum samples.
SETTING: Academic ART program. PATIENT(S): One sample of frozen day 3 serum from women with < or = 6 retrieved oocytes (n = 28) compared with women with > or = 11 oocytes retrieved (n = 79) in preparation for IVF. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Comparison of day 3 serum MIS levels between two groups of women. Other comparisons included maximum serum E(2) concentrations, number of retrieved oocytes, and percentage of mature oocytes between groups. RESULT(S): Mean serum MIS concentrations were 1.0 +/- 0.4 ng/mL compared with 2.5 +/- 0.3 ng/mL, or more than a 2.5-fold greater serum concentration of MIS in the group with > or = 11 oocytes retrieved compared with in the group with < or = 6 retrieved oocytes. CONCLUSION(S): These data demonstrate an association between early follicular phase serum MIS and the number of retrieved oocytes. Higher day 3 serum MIS concentrations were associated with greater number of retrieved oocytes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11872196     DOI: 10.1016/s0015-0282(01)03201-0

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  95 in total

1.  Impact of cancer therapies on ovarian reserve.

Authors:  Clarisa R Gracia; Mary D Sammel; Ellen Freeman; Maureen Prewitt; Claire Carlson; Anushree Ray; Ashley Vance; Jill P Ginsberg
Journal:  Fertil Steril       Date:  2011-12-02       Impact factor: 7.329

2.  Changes in plasma müllerian-inhibiting substance and brain-derived neurotrophic factor after chemotherapy in premenopausal women.

Authors:  Muhammad Faisal Aslam; Zaher O Merhi; Safaa Ahmed; Oumar Kuzbari; David B Seifer; Howard Minkoff
Journal:  Fertil Steril       Date:  2011-04       Impact factor: 7.329

3.  Single and repeated GnRH agonist stimulation tests compared with basal markers of ovarian reserve in the prediction of outcome in IVF.

Authors:  D J Hendriks; F J Broekmans; L F J M M Bancsi; C W N Looman; F H de Jong; E R te Velde
Journal:  J Assist Reprod Genet       Date:  2005-02       Impact factor: 3.412

4.  Prediction of high ovarian response to controlled ovarian hyperstimulation: anti-Müllerian hormone versus small antral follicle count (2-6 mm).

Authors:  Abbas Aflatoonian; Homa Oskouian; Shahnaz Ahmadi; Leila Oskouian
Journal:  J Assist Reprod Genet       Date:  2009-06-20       Impact factor: 3.412

5.  Is anti-Müllerian hormone associated with IVF outcomes in young patients with diminished ovarian reserve?

Authors:  Nigel Pereira; Robert Setton; Allison C Petrini; Jovana P Lekovich; Rony T Elias; Steven D Spandorfer
Journal:  Womens Health (Lond)       Date:  2016-02-22

6.  Anti-Mullerian hormone normogram in an Irish subfertile population.

Authors:  M N Naasan; C Harrity; L Pentony; E Mocanu
Journal:  Ir J Med Sci       Date:  2014-02-23       Impact factor: 1.568

7.  To what extent does Anti-Mullerian Hormone contribute to a better prediction of live birth after IVF?

Authors:  Catherine Rongieres; Carolina Colella; Philippe Lehert
Journal:  J Assist Reprod Genet       Date:  2014-11-05       Impact factor: 3.412

8.  Subclinical impairment of ovarian reserve in systemic lupus erythematosus patients with normal menstruation not using alkylating therapy.

Authors:  Wenhong Ma; Zhongping Zhan; Xiaoyan Liang; Jianhui Chen; Xingfang Huang; Caiyun Liao
Journal:  J Womens Health (Larchmt)       Date:  2013-12       Impact factor: 2.681

9.  Antimüllerian hormone and antral follicle count are lower in female cancer survivors and healthy women taking hormonal contraception.

Authors:  Lauren N C Johnson; Mary D Sammel; Katherine E Dillon; Lara Lechtenberg; Allison Schanne; Clarisa R Gracia
Journal:  Fertil Steril       Date:  2014-06-14       Impact factor: 7.329

10.  Intrafollicular antimüllerian hormone levels predict follicle responsiveness to follicle-stimulating hormone (FSH) in normoandrogenic ovulatory women undergoing gonadotropin releasing-hormone analog/recombinant human FSH therapy for in vitro fertilization and embryo transfer.

Authors:  Daniel A Dumesic; Timothy G Lesnick; Jacques P Stassart; G David Ball; Ashley Wong; David H Abbott
Journal:  Fertil Steril       Date:  2009-07       Impact factor: 7.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.